^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Positive Breast Cancer
    Drug:Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for HER2 Negative Breast Cancer)
    New
    Excerpt:
    Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer:...in combination with an aromatase inhibitor…in combination with fulvestrant in women who have received prior endocrine therapy.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

    Excerpt:
    ...Patients must have histologically confirmed HER2+ and hormone receptor positive (ER+ and/or PR+), metastatic breast cancer....
    Trial ID:
    PATINA
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Breast Cancer Res
    Title:

    Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.

    Published date:
    03/24/2021
    Excerpt:
    A total of 1430 patients with ≥ 3 months of follow-up received palbociclib plus letrozole or letrozole alone in the first-line setting between February 3, 2015, and February 28, 2019….Palbociclib combination treatment was associated with significantly longer median rwPFS compared to letrozole alone (20.0 vs 11.9 months; hazard ratio [HR], 0.58; 95% CI, 0.49–0.69; P < 0.0001).
    Secondary therapy:
    letrozole
    DOI:
    10.1186/s13058-021-01409-8
    Trial ID:
    NCT04176354